Tag: biosciences
-
ONK Therapeutics Snags $21.5M for NK Cell Therapies
San Diego- and Galway, Ireland-based ONK Therapeutics announced today that it has raised $21.5M in its Series A funding. The funding was led by Acorn Bioventures and ALSHC, plus Cormorant Asset Management. The startup says it is developing optimally en…
-
Novoron Biosciences Picks Up $3M
San Diego-based Novoron Biosciences, a biotech company that is developing therapies aimed at reversing central nervous system (CNS) damage due to spinal cord injuries, has raised $3M in a seed fudning round. The company came from Two Bear Capital. Acco…
-
Shoreline Biosciences Names Chief Business Officer
San Diego-based biotechnology company Shoreline Biosciences said this morning that it has named Scott Forrest, Ph.D., as its Chief Business Officer. Forrest was most recently Chief Financial Officer at Autobahn Therapeutics, and also served at Inceptio…
-
Replicate Biosciences Gets $40M
San Diego-based Replicate Bioscience, which is looking to use self-replicating RNA (srRNA) to treat cancer, autoimmune, inflammatory disorders and other diseases, has raised $40M in its Series A funding. The funding was led by life sciences venture cap…
-
Avidity Biosciences Shuffles Board
La Jolla-based biopharmaceuticals developer Avidity Biosciences has shuffled its board, saying today that it has named Eric Mosbrooker to its board, with Roderick Wong, M.D. departing. Mosbrooker is the chief operations officer for Cognoa. He also has …
-
Mirati Therapeutics Gets $65M In Deal With China’s Zai Lab
San Diego-based oncology therapeutics developer Mirati Therapeutics said this morning that it has received $65M in an upfront payment, as part of a deal with Chinese company Zai Lab. According to the to companies,t he two have entered into a collaborat…
-
Evofem Biosciences Raises $50M In Offering
San Diego-based Evofem Biosciences, a developer of biopharmaceuticals for female reproductive health, reported it raised $50M in its previously announced public offering. It said it will net approximately $46.6M after underwriting discounts, commission…
-
Evofem Prices $50M Offering
San Diego-based Evofem Biosciences, which is developing biopharmaceuticals for women’s contraception and related areas, says it has priced a $50M, public offering, and also will receive up to an additoinal $50M upon exercise of accompanying short-term …